Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
AMINOSYN-HF 8% vs TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Renal: >90% as amino acids and metabolites; fecal: <5%.
Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution